Press Releases

View Archive: 2011 | 2010 | 2009 | 2008 | 2007

12.3.09
Hyperion Therapeutics Enrolls First Patient in Phase II Hepatic Encephalopathy Trial

10.27.09
Hyperion Therapeutics Announces First Patient Enrolled in Pivotal Trial in Patients with Urea Cycle Disorders

9.18.09
Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference

9.17.09
HYPERION THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR HPN-100 FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY

9.15.09
Hyperion Therapeutics Announces First Patient Enrolled in Trial in Children with Urea Cycle Disorders

7.7.09
Hyperion Therapeutics Receives Special Protocol Assessment Approval from FDA for Pivotal Phase III Trial in Urea Cycle Disorders

6.30.09
Hyperion Therapeutics Raises $60 Million Series C

6.2.09
Hyperion Therapeutics Announces Results of Phase I Study in Patients with Liver Cirrhosis

5.5.09
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders

3.30.09
Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders

Recent Press Releases